NEW YORK, Feb. 9, 2016 /PRNewswire/ --
Contracted drug production – stay ahead now by exploring leading companies' prospects
How are pharma contract manufacturing organisations (CMOs) performing? Visiongain's updated report shows you their prospects to 2025. You discover that outsourcing industry's results, trends, opportunities and potentials, also with predicted revenues and profits.
Our study analyses 30 top CMOs. There you see how revenues from drug production services can increase. You explore trends, technologies and opportunities shaping that industry. Discover that market's potential, benefiting your reputation for commercial insight.
That way you find analysis on established and emerging companies across the world. Read on, please, to scan the leading companies and see revenue prediction for their industry.
Forecasts and other data to help you stay ahead, benefiting your influence
In our new study you find analytical profiles of 30 top contractors, and analyses of their overall industry. You discover historical data, market and sales shares, growth rates and revenue forecasts. Also explore qualitative analyses, business outlooks and developments.
Our study gives you 185 tables, 111 charts and three interviews with companies.
That investigation also shows you prospects for these outsourced production segments at world level, including their overall revenue forecasts to 2025:
- Active pharmaceutical ingredients (API) production
- Finished dosage formulations (FDF) manufacturing.
In particular, biologics and biosimilars hold promise. New therapies – including antibody-drug conjugates, high potency APIs and regenerative medicines – increasingly interest CMOs and clients.
Discover, then, what the future holds. The following sections highlight what our research and analyses give you, to benefit planning, proposals and presentations.
Company profiles – explore commercial activities, results, competition and prospects
Our report analyses 30 leading companies. The content of each profile differs, depending on the organisation. In general, though, a profile gives you the following information:
- Overview of the company's contract manufacturing services and operations
- Analysis of recent financial performance – annual revenue for CMO services, including some data on operating profit and margins
- Assessment of developments – activities, acquisitions, production capacity, deals, new service offerings and collaborations
- SWOT analysis – a firm's strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2015 onwards
- Forecasting of pharmaceutical manufacturing revenue to 2025 (for 26 firms), as well as projected operating profit and margin for some companies.
Pharmaceutical developers, producers and marketers will increasingly use CMOs. With our study you discover what that industry's participants offer – along with their trends and revenue potentials – helping you stay ahead in knowledge and benefit your authority.
European contract manufacturing organisations
Our study gives you discussions, financial analyses and commercial outlooks for 14 European CMOs, including these firms:
- Evonik Degussa
- Royal DSM
- Boehringer Ingelheim
- Vetter Pharma.
Discover what the future holds for those pharma service providers, including revenue outlooks to 2025. What profitability and other achievements are possible?
CMOs based in the US and Japan
Our report also shows you developments and business outlooks for seven other international drug production contractors:
- Catalent Pharma Solutions
- Baxter BioPharma Solutions
- AbbVie Contract Manufacturing
- Pfizer CentreSource
- Daito Pharmaceutical
- Nipro Corporation.
Our work reveals where sales growth can occ
Read the full report: http://www.reportlinker.com/p03360042-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: firstname.lastname@example.org
Intl: +1 339-368-6001